Explanipedia

Hematology-oncology provider perspectives regarding lymphoma treatment and cardioprotective strategies in patients with lymphoma at high risk for heart failure Open

Emily R. Anderson, Yun Young Choi, Rachel J. Buchsbaum, Andreas K. Klein, Bonnie Ky , et al. · 2025

The optimal treatment of patients with diffuse large B-cell lymphoma (DLBCL) or Hodgkin lymphoma (HL) with preexisting cardiomyopathy is uncertain. An anonymous, electronic survey was distributed by e-mail to three US lymphoma cooperative …

Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma Open

James N. Gerson, Elizabeth A. Handorf, Diego Villa, Alina S. Gerrie, Parv Chapani , et al. · 2023

Mantle cell lymphoma (MCL) is a B-cell non-Hodgkin lymphoma; data indicate that blastoid and pleomorphic variants have a poor prognosis. We report characteristics and outcomes of patients with blastoid/pleomorphic variants of MCL. We retro…

Association of Preexisting Heart Failure With Outcomes in Older Patients With Diffuse Large B-Cell Lymphoma Open

Jenica Upshaw, Jason Nelson, Angie Mae Rodday, Anita J. Kumar, Andreas K. Klein , et al. · 2023

Importance Anthracycline-containing regimens are highly effective for diffuse large B-cell lymphoma (DLBCL); however, patients with preexisting heart failure (HF) may be less likely to receive anthracyclines and may be at higher risk of ly…

Safety of AFM11 in the treatment of patients with B-cell malignancies: findings from two phase 1 studies Open

Max S. Topp, Monika Długosz‐Danecka, Aleksander B. Skotnicki, Galina Salogub, Andreas Viardot , et al. · 2023

Developing an engaging and accessible clinical research training program for new investigators – ADDENDUM Open

Kris M. Markman, Sarah K. Brewer, Andreas K. Klein, Britta Magnuson · 2023

An abstract is not available for this content. As you have access to this content, full HTML content is provided on this page. A PDF of this content is also available in through the ‘Save PDF’ action button.

T083: The Effect of Heart Failure on Management and Outcomes of Older Patients with Hodgkin Lymphoma Open

Jenica Upshaw, Jason Nelson, Angie Mae Rodday, Anita J. Kumar, Andreas K. Klein , et al. · 2022

Figure 1: Cumulative incidence of lymphoma mortality (blue), cardiovascular mortality (red) and all-cause mortality (black). Dashed line represents patients with heart failure at the time of lymphoma diagnosis and solid lines patients with…

Developing an engaging and accessible clinical research training program for new investigators Open

Kris M. Markman, Sarah K. Brewer, Andreas K. Klein, Britta Magnuson · 2022

Clinicians who are interested in becoming principal investigators struggle to find and complete training that adequately prepares them to conduct safe, well-designed clinical and translational research. Degree programs covering these skill…

Safety of AFM11 in the treatment of patients with B-cell malignancies: Findings from two phase 1 studies Open

Max S. Topp, Monika Długosz‐Danecka, Aleksander B. Skotnicki, Galina Salogub, Andreas Viardot , et al. · 2022

BackgroundThe prognosis for patients with relapsed and/or refractory (R/R) non-Hodgkin’s lymphoma (NHL) or acute lymphoblastic leukaemia (ALL) remains poor, with existing treatments having significant side effects. Developed for the treatm…

Pembrolizumab plus dinaciclib in patients with hematologic malignancies: the phase 1b KEYNOTE-155 study Open

Gareth P. Gregory, Shaji Kumar, Ding Wang, Daruka Mahadevan, Patricia Walker , et al. · 2021

Preclinical data demonstrated that combining an anti–programmed cell death 1 (PD-1) inhibitor with a cyclin-dependent kinase 9 (CDK9) inhibitor provided enhanced antitumor activity with no significant toxicities, suggesting this combinatio…

499. Rapid and Sustained Decline in CXCL-10 (IP-10) Annotates Clinical Outcomes Following TNF-α Antagonist Therapy in Hospitalized Patients with Severe and Critical COVID-19 Respiratory Failure Open

Courtney Schroeder, Hilal Hachem, Amandeep Godara, Daniel Fein, Hashim Mann , et al. · 2021

Background TNFα and IFN-γ may synergize to induce cytokine-driven lethal hyperinflammation and immune exhaustion in COVID-19 illness. Methods To assess TNFα-antagonist therapy, 18 hospitalized adults with hypoxic respiratory failure and CO…

HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis Open

Juan Pablo Alderuccio, Adam J. Olszewski, Andrew M. Evens, Graham P. Collins, Alexey V. Danilov , et al. · 2021

Data addressing prognostication in patients with HIV related Burkitt lymphoma (HIV-BL) currently treated remain scarce. We present an international analysis of 249 (United States: 140; United Kingdom: 109) patients with HIV-BL treated from…

Rapid and sustained decline in CXCL-10 (IP-10) annotates clinical outcomes following TNF-α antagonist therapy in hospitalized patients with severe and critical COVID-19 respiratory failure Open

Hilal Hachem, Amandeep Godara, Courtney Schroeder, Daniel Fein, Hashim Mann , et al. · 2021

Background A feed-forward pathological signaling loop generated by TNFα and IFN-γ in inflamed lung tissue, driving CXCL-10 (IP-10) and CXCL-9 chemokine-mediated activated T-cell and monocyte/macrophage tissue recruitment, may define, susta…

SURVIVAL FOLLOWING FIRST RELAPSE IN YOUNGER PATIENTS WITH MANTLE CELL LYMPHOMA Open

Reem Karmali, Alexandra M. Donovan, N. Wagner‐Johntson, Marcus Messmer, Amitkumar Mehta , et al. · 2021

Introduction: Mantle cell lymphoma (MCL) is an incurable B-cell non-Hodgkin lymphoma. Though most patients achieve remission following induction therapy, relapse is inevitable. We previously described the outcome following upfront treatmen…

Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort study Open

Adam Zayac, Andrew M. Evens, Alexey V. Danilov, Stephen D. Smith, Deepa Jagadeesh , et al. · 2021

Central nervous system (CNS) involvement in Burkitt lymphoma (BL) poses a major therapeutic challenge, and the relative ability of contemporary regimens to treat CNS involvement remains uncertain. We described prognostic significance of CN…

Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers Open

Andrew M. Evens, Alexey V. Danilov, Deepa Jagadeesh, Amy Sperling, Seo‐Hyun Kim , et al. · 2021

We examined adults with untreated Burkitt lymphoma (BL) from 2009 to 2018 across 30 US cancer centers. Factors associated with progression-free survival (PFS) and overall survival (OS) were evaluated in univariate and multivariate Cox mode…

Rapid and sustained decline in CXCL-10 (IP-10) annotates clinical outcomes following TNFα-antagonist therapy in hospitalized patients with severe and critical COVID-19 respiratory failure Open

Hilal Hachem, Amandeep Godara, Courtney Schroeder, Daniel Fein, Hashim Mann , et al. · 2021

Background: A feedforward pathological signaling loop generated by TNFα and IFN-γ synergy in the inflamed lung, driving CXCL-10 (IP-10) and CXCL-9 chemokine-mediated activated T-cell and monocyte/macrophage tissue recruitment, may define t…

PS1075 ANTITUMOR ACTIVITY OF PEMBROLIZUMAB PLUS DINACICLIB IN PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA: THE PHASE 1B KEYNOTE‐155 STUDY Open

Gareth P. Gregory, Patricia Walker, Daruka Mahadevan, D. Wang, Julie Chang , et al. · 2019

Background: The cyclin‐dependent kinase inhibitor dinaciclib induces apoptosis by CDK9 inhibition with antitumor activity in preclinical syngeneic lymphoma models and early phase trials of hematologic malignancies including diffuse large B…

ANTITUMOR ACTIVITY OF PEMBROLIZUMAB PLUS DINACICLIB IN PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA: THE PHASE 1B KEYNOTE‐155 STUDY Open

Gareth P. Gregory, Patricia Walker, Daruka Mahadevan, Dee Dee Wang, Julie Chang , et al. · 2019

Introduction: KEYNOTE-155 (NCT02684617) evaluated the antitumor activity of pembrolizumab (pembro) plus dinaciclib in patients (pts) with relapsed/refractory (rr) CLL, MM, and DLBCL. Here we present data from an interim analysis of safety …

Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era Open

James N. Gerson, Elizabeth A. Handorf, Diego Villa, Alina S. Gerrie, Parv Chapani , et al. · 2019

PURPOSE Mantle cell lymphoma (MCL) is a B-cell lymphoma characterized by cyclin D1 expression. Autologous hematopoietic cell transplantation (AHCT) consolidation after induction chemotherapy is often used for eligible patients; however, th…

Daratumumab binds to mobilized CD34+ cells of myeloma patients in vitro without cytotoxicity or impaired progenitor cell growth Open

Xun Ma, Sandy W. Wong, Ping Zhou, Chakra P. Chaulagain, Parul Doshi , et al. · 2018

Clinicopathologic characteristics of secondary squamous cell carcinoma of head and neck in survivors of allogeneic hematopoietic stem cell transplantation for hematologic malignancies Open

Chakra P. Chaulagain, Kellie Sprague, Monika Pilichowska, Janet M. Cowan, Andreas K. Klein , et al. · 2018

The risk of late complications including secondary malignancies is increased in long-term survivors of allogeneic hematopoietic stem cell transplants (HSCT). There is limited literature on the biological behavior and clinical features of s…

Assessment of a shortened informed consent form for pediatric research: a pilot study Open

Peter D. Murray, Barbara E. Bierer, Steven Hirschfeld, Andreas K. Klein, Jonathan M. Davis · 2018

Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure Open

Sonali M. Smith, James Godfrey, Kwang Woo Ahn, Alyssa DiGilio, Sairah Ahmed , et al. · 2018

BACKGROUND Early treatment failure (ETF) in follicular lymphoma (FL), defined as relapse or progression within 2 years of frontline chemoimmunotherapy, is a newly recognized marker of poor survival and identifies a high‐risk group of patie…

Cost Implications of Comorbidity for Autologous Stem Cell Transplantation in Elderly Patients with Multiple Myeloma Using SEER-Medicare Open

Gunjan L. Shah, Aaron N. Winn, Pei‐Jung Lin, Andreas K. Klein, Kellie Sprague , et al. · 2016

Comorbidity is more common in older patients and can increase the cost of care by increasing toxicity. Using the SEER-Medicare database from 2000 to 2007, we examined the costs and life-year benefit of Auto-HSCT for MM patients over the ag…

Survival Analyses and Prognosis of Plasma-Cell Myeloma and Plasmacytoma-Like Posttransplantation Lymphoproliferative Disorders Open

Aaron S. Rosenberg, Robin Ruthazer, Jessica K. Paulus, David M. Kent, Andrew M. Evens , et al. · 2016

Perforation of the Colon During Imatinib Mesylate (Gleevec) Treatment in a Patient with Chronic Myeloid Leukemia (CML) Open

Najla El Jurdi, Mark S. Bankoff, Andreas K. Klein, Muhammad Wasif Saif · 2016

Imatinib (Gleevec; STI-571) is a tyrosine-kinase inhibitor (TKI) used in the treatment of multiple cancers, most notably Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) as well as gastrointestinal stromal tumor (G…

Hodgkin lymphoma post‐transplant lymphoproliferative disorder: A comparative analysis of clinical characteristics, prognosis, and survival Open

Aaron S. Rosenberg, Andreas K. Klein, Robin Ruthazer, Andrew M. Evens · 2016

Hodgkin lymphoma post‐transplant lymphoproliferative disorder (HL‐PTLD) is an uncommon PTLD with unclear prognosis and differences between HL‐PTLD and immunocompetent HL are not well defined. Patient characteristics were compared among 192…

The Quality Management Group Oral Session Open

Pere Barba, Linda J. Burns, Mark R. Litzow, Mark Juckett, Krishna V. Komanduri , et al. · 2016

Success of an International Learning Healthcare System in Hematopoietic Cell Transplantation: The American Society of Blood and Marrow Transplantation Clinical Case Forum Open

Pere Barba, Linda J. Burns, Mark Juckett, Krishna V. Komanduri, Mark R. Litzow , et al. · 2016

The ASBMT Clinical Case Forum (CCF) was launched in 2014 as an online secure tool to enhance interaction and communication among hematopoietic cell transplantation (HCT) professionals worldwide through the discussion of challenging clinica…

Success of an International Learning Health Care System in Hematopoietic Cell Transplantation: The American Society of Blood and Marrow Transplantation Clinical Case Forum Open

Pere Barba, Linda J. Burns, Mark R. Litzow, Mark Juckett, Krishna V. Komanduri , et al. · 2015

Andreas K. Klein YOU? Author Swipe